Collaboration with The National Cell and Tissue Centre

Collaboration with The National Cell and Tissue Centre

(18. 9. 2014)

Pharmnet s.r.o. and Národní Centrum Tkání a Buněk a.s. (The National Cell and Tissue Centre, NCTB), member of PrimeCell Therapeutics group, are proud to announce joint collaboration on the clinical trial sponsored by Innovacell Biotechnologie, GmbH, Austrian innovative company focusing on cell-tissue therapy for the treatment of incontinence

The aim of this double blind, placebo controlled trial is determination of the optimal dose of Advanced Therapy Medicinal Product (ATMP) for the treatment of fecal incontinence.

 This project  is for both companies the first controlledclinical trial with human tissue as a source for the manufacturing of an innovative cell therapy product contracted by a foreign Sponsor conducted not only according to regulations on clinical trials but also following regulations related to provision of quality and safety of human tissues and cells designated for use in humans.

 For 20 years Pharmnet provides highly qualified services in clinical development with a deep insight of the study staff in the purpose, design, clinical context and ethical aspects of each clinical study, assuring clinical subject’s safety, highest possible data validity, and time adherence.

NCTB, member of PrimeCell Therapeutics group, is innovative biotechnology company with highly qualifiedspecialists focused on the development and manufacturing of the autologous cell therapy products with the status of a medical and tissue center and simultaneously that of a pharmaceutical manufacturer.

Across Alliance
Season's Greetings and Happy New Year!Pharmnet's youngest generation seems to have a fairly clear vision of the
Pharmnet © 2022